DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
Status: Forecasted
Posted date: May 4, 2026
Archive date: October 30, 2026
Close date: September 30, 2026
Opportunity ID: 362197
Opportunity number: HT942526ALSRPTIA
Opportunity category: Discretionary
Agency name: Dept. of the Army -- USAMRAA
Agency code: DOD-AMRAA
Award floor: $0
Award ceiling: $0
Cost sharing required: No
Funding Instrument Types
- Grant
Category of Funding Activity
- Science and Technology and other Research and Development
Eligible Applicants
- Unrestricted
Categories (use these for quoted searches)
- agency_code:dod_amraa
- category_of_funding_activity:science_and_technology_and_other_research_and_development
- cost_sharing_or_matching_requirement:false
- eligible_applicants:unrestricted
- funding_instrument_type:grant
- opportunity_category:discretionary
- status:forecasted
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.